An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor

Ahmadzadeh, 2020, The risk factors associated with MERS-CoV patient fatality: a global survey, Diagnostic microbiology and infectious disease, 96(3) Amin, 2021, Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors, Bioorg. Med. Chem., 29, 10.1016/j.bmc.2020.115860 Bagchi, 2017, High throughput virtual screening based discovery of dengue protease inhibitor, Journal of Pharmaceutical Chemistry, 4, 35, 10.14805/jphchem.2017.art92 Bagchi, 2017, High throughput virtual screening based discovery of dengue protease inhibitor., 4, 35 Bajgain, 2021, Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature, American journal of infection, control49(2), 238 Bergdorf, M., S. Baxter, C. A. Rendleman and D. E. Shaw (2015). “Desmond/GPU Performance as of October 2015.” DE Shaw research. Biering, 2021, “Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2.” ACS infectious, diseases7(8), 2337 Brogi, 2020, In silico methods for drug design and discovery, 8:, 612 Chakraborty, 2020, SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options, Eur Rev Med Pharmacol Sci, 24, 4016 Chakraborty, 2020, Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak, Archives of medical, research51(7), 728 Cucinotta, 2020, WHO declares COVID-19 a pandemic, Acta Bio Medica: Atenei Parmensis, 91, 157 Darvas, F., G. Keseru, A. Papp, G. Dorman, L. Urge and P. J. C. t. i. m. c. Krajcsi (2002). “In silico and ex silico ADME approaches for drug discovery.” 2(12): 1287-1304. Deng, Y., W. Liu, K. Liu, Y.-Y. Fang, J. Shang, L. Zhou, K. Wang, F. Leng, S. Wei and L. Chen (2020). “Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.” Chinese medical journal133(11): 1261. Ejaz, 2020, COVID-19 and comorbidities: Deleterious impact on infected patients, Journal of Infection and Public Health, 13, 1833, 10.1016/j.jiph.2020.07.014 Hilgenfeld, 2014, From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design, The FEBS, journal281(18), 4085, 10.1111/febs.12936 Javorac, 2020, An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease, Food Chem. Toxicol., 111639 Jin, 2020, Structure of M pro from SARS-CoV-2 and discovery of its inhibitors, Nature, 582, 289, 10.1038/s41586-020-2223-y Leelananda, 2016, Computational methods in drug discovery, Beilstein journal of organic, chemistry12(1), 2694, 10.3762/bjoc.12.267 Li, L. q., T. Huang, Y. q. Wang, Z. p. Wang, Y. Liang, T. b. Huang, H. y. Zhang, W. Sun and Y. Wang (2020). “COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis.” Journal of medical virology 92(6): 577-583. Liu, 2020, “The crystal structure of COVID-19 main protease in complex with an inhibitor, N3.”, 10 Mahase, 2020, Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate, British Medical Journal Publishing, Group. Makhouri, F. R. and J. B. J. C. T. i. M. C. Ghasemi (2018). “Combating diseases with computational strategies used for drug design and discovery.” 18(32): 2743-2773. Mali, 2018, Computational studies on imidazo [1, 2-a] pyridine-3-carboxamide analogues as antimycobacterial agents: Common pharmacophore generation, atom-based 3D-QSAR, molecular dynamics simulation, QikProp, molecular docking and prime MMGBSA approaches, Open Pharmaceutical Sciences Journal, 5, 12, 10.2174/1874844901805010012 Mandour, 2020, A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease, J. Biomol. Struct. Dyn., 1 Marcolino, 2020, What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results, Eur. J. Pharmacol., 887, 10.1016/j.ejphar.2020.173467 Mary, S. J., M. U. M. Siddique, S. Pradhan, V. Jayaprakash, C. J. S. A. P. A. M. James and B. Spectroscopy (2021). “Quantum chemical insight into molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT–IR, FT–Raman), drug likeness and molecular docking of the novel anti COVID-19 molecule 2-[(4, 6-diaminopyrimidin-2-yl) sulfanyl]-N-(4-fluorophenyl) acetamide-dimer.” 244: 118825. Mithal, 2021, High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 169, 10.1016/j.dsx.2020.12.029 Pan, 2020, Viral load of SARS-CoV-2 in clinical samples, The Lancet infectious, diseases20(4), 411, 10.1016/S1473-3099(20)30113-4 Roe, 2021, Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19, J. Gen. Virol., 001558 Romano, 2019, Informatics and computational methods in natural product drug discovery: A review and perspectives, Front. Genet., 10, 368, 10.3389/fgene.2019.00368 Schrodinger, L., 2011. Schrodinger software suite. New York: Schrödinger, LLC670. Siddique, 2018, Comparative Shape and Electrostatic Study of Highly Potent and Selective CYP1B1 Inhibitor: Assessment of Active Site of CYP1B1 by Binding Mode Analysis Using Site, Map Tool, 52, 159 Siddique, 2020, Comparative Computational Studies on Selective CytochromeP450 1B1 Inhibitors, Int. J. Bioautomat., 24, 213, 10.7546/ijba.2020.24.3.000537 Siddique, 2020, Comparative Computational Studies on Selective CytochromeP450 1B1 Inhibitors, 24, 213 Sonawane, V., M. U. M. Siddique, S. S. Jadav, B. N. Sinha, V. Jayaprakash and B. Chaudhuri (2019). “Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.” European journal of medicinal chemistry165: 115-132. Stasi, 2020, Treatment for COVID-19: An overview, Eur. J. Pharmacol., 173644 Tang, 2020, Laboratory diagnosis of COVID-19: current issues and challenges, J. Clin. Microbiol., 58, 10.1128/JCM.00512-20 To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet. Infect. Dis, 20, 565, 10.1016/S1473-3099(20)30196-1 Tong, 2002, Viral proteases, Chem. Rev., 102, 4609, 10.1021/cr010184f Touret, 2020, In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Scientific reports, 10(1), 1 Trezza, 2020, An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors, Scientific Reports, 10(1), 1 Usman, 2018, Combined protein and ligand based physicochemical aspects of molecular recognition for the discovery of CDK9 inhibitor, Gene Reports, 13, 212, 10.1016/j.genrep.2018.10.011 Verdugo-Paiva, 2020, Lopinavir/ritonavir for COVID-19: A living systematic review, Medwave, 20, e7966, 10.5867/medwave.2020.06.7966 Wang, 2020, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, Journal of chemical information and modelling, 60(6), 3277, 10.1021/acs.jcim.0c00179 Wang, 2020, Structure of Mpro from COVID-19 virus and discovery of its inhibitors, Nature WHO. (2019). “Middle East respiratory syndrome coronavirus (MERS-CoV).”. Zhai, P., Y. Ding, X. Wu, J. Long, Y. Zhong and Y. Li (2020). “The epidemiology, diagnosis and treatment of COVID-19.” International journal of antimicrobial agents55(5): 105955.